Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.49 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.49 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.48 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21540009 | 1.00 | TERT (0.53) | TERTPOLBFUT5RNASELP2RY2 | |
| SCHEMBL20782764 | 1.00 | TERT (0.53) | TERTPOLBFUT5RNASELP2RY2 | |
| SCHEMBL20324868 | 1.00 | TERT (0.53) | TERTPOLBFUT5RNASELP2RY2 | |
| SCHEMBL18822882 | 0.95 | TERT (0.52) | TERTPOLBFUT5P2RY2P2RY4 | |
| SCHEMBL26570660 | 0.95 | TERT (0.52) | TERTPOLBFUT5RNASELP2RY2 | |
| SCHEMBL20782763 | 0.94 | POLB (0.58) | TERTPOLBFUT5P2RY2P2RY4 | |
| SCHEMBL22765983 | 0.94 | TERT (0.48) | TERTPOLBFUT5RNASELP2RY2 | |
| SCHEMBL22765945 | 0.94 | TERT (0.48) | TERTPOLBFUT5RNASELP2RY2 | |
| SCHEMBL25512666 | 0.93 | TERT (0.54) | TERTPOLBFUT5P2RY2P2RY4 | |
| SCHEMBL20327069 | 0.92 | RNASEL (0.48) | POLBRNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2020-09-17 | — | — | US | disclosed |
| WO-2018118664-A1 | COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | STING1, BID, VIP | TERT 3897/4885POLB 2971/4885FUT5 1645/4885 |
| US-10906930-B2 | Compositions and methods for activating “stimulator of interferon gene”-dependent signalling | STING1, IRF3, CGAS | TERT 4069/4885POLB 1121/4885FUT5 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.